Introduction
Paracetamol is one of the most widely used medicines in the world today, and it appears on the World Health Organization's List of Essential Medicines. As the reference analgesic and antipyretic, available over the counter in many countries, it plays a central role in treating mild-to-moderate pain and fever.
Yet behind this everyday familiarity lies a long and winding history: an early discovery, decades of neglect, and then a spectacular scientific rehabilitation.
Origins and Discovery
The molecule was first synthesized in 1877 by American chemist Harmon Northrop Morse at Johns Hopkins University, through the reduction of para-nitrophenol in glacial acetic acid. At the time, the synthesis remained a laboratory curiosity with no immediate medical application.
In 1887, pharmacologist Joseph von Mering tested paracetamol in humans but wrongly concluded that it caused significant kidney toxicity. He favored phenacetin and acetanilide instead — the latter marketed as "Antifebrin" from 1886 — two related compounds that would go on to dominate the antipyretic market for more than half a century. Paracetamol fell into relative obscurity.
Rehabilitation and Development
The real turning point came in 1948, when American pharmacologists Bernard Brodie and Julius Axelrod showed that the analgesic effect of acetanilide and phenacetin actually came from a shared active metabolite: paracetamol. They also established that the blood toxicity (methemoglobinemia) once blamed on paracetamol actually originated from the parent compounds. The molecule was thus fully rehabilitated.
Paracetamol reached the US market as early as 1953, launched by Sterling-Winthrop under the name Panadol, followed in 1955 by McNeil Laboratories under what became a globally famous brand: Tylenol. In the United Kingdom, it was marketed from 1956 in 500 mg tablets. Its use has grown steadily ever since.
Pharmacological Properties and Mechanism of Action
Paracetamol has analgesic (pain-relieving) and antipyretic (fever-reducing) properties, but virtually no anti-inflammatory action at usual doses — a key difference from non-steroidal anti-inflammatory drugs (NSAIDs).
Its mechanism of action, long debated, is still only partially understood. It weakly inhibits cyclo-oxygenases (COX), mainly within the central nervous system rather than at peripheral sites, which explains its central effect on pain and fever without a marked anti-inflammatory action and without the digestive side effects associated with NSAIDs. One metabolite, AM404, is also thought to act on the endocannabinoid and serotonergic systems as well as on TRPV1 receptors.
Pharmacokinetics, Safety, and Toxicity
After oral administration, paracetamol is rapidly absorbed and metabolized by the liver, mainly through glucuronidation and sulfation. At therapeutic doses, it is remarkably well tolerated.
In cases of overdose, a secondary metabolic pathway produces a hepatotoxic metabolite, NAPQI (N-acetyl-p-benzoquinone imine), which depletes the liver's glutathione reserves and can cause potentially fatal liver necrosis. The reference antidote is N-acetylcysteine, which is most effective when given early. It is this narrow safety margin in cases of abuse that justifies strict warnings on the maximum daily dose, typically 3 to 4 g in adults.
Use in the Pharmaceutical Industry
Paracetamol is formulated into a wide range of dosage forms: tablets (conventional, effervescent, film-coated, orodispersible), capsules, syrups and pediatric oral solutions, suppositories, and hospital intravenous injectable forms.
From a formulation standpoint, it is a high-dose API (often 500 mg per tablet) known for its poor compressibility: it is difficult to form robust tablets without additives. Shaping it therefore requires suitable excipients — binders, direct-compression diluents such as microcrystalline cellulose or lactose, disintegrants, and lubricants. It is frequently combined with other active ingredients, including caffeine, codeine, tramadol, or vitamin C. It is precisely this kind of high-volume API where our API sourcing capabilities make the difference for manufacturers managing their supply.